Details of the Drug

General Information of Drug (ID: DMBLX7U)

Drug Name
Evinacumab
Synonyms REGN1500; ANGPTL-1 antibody
Indication
Disease Entry ICD 11 Status REF
Hypercholesterolaemia 5C80.0 Approved [1]
Elevated C-reactive protein MA14.15 Phase 2 [2]
Familial hypercholesterolemia 5C80.00 Phase 2 [3]
Affected Organisms
Humans and other mammals
ATC Code
C10AX17: Evinacumab
C10AX: Other lipid modifying agents
C10A: LIPID MODIFYING AGENTS, PLAIN
C10: LIPID MODIFYING AGENTS
C: CARDIOVASCULAR SYSTEM
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 689 mg/L [4]
Metabolism
The drug is metabolized via the catabolic pathways into smaller peptides and amino acids [4]
Vd
The volume of distribution (Vd) of drug is 4.8 L [4]
Cross-matching ID
UNII
T8B2ORP1DW
DrugBank ID
DB15354
TTD ID
D03WOG
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-related protein 3 (ANGPTL3) TTUO98L ANGL3_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 FDA Approved Drug Products: Evkeeza (evinacumab-dgnb) for intravenous injection